美國的外科用止血劑·組織內密封材料·防粘黏薄膜市場:2012年

美國的外科用止血劑·組織內密封材料·防粘黏薄膜市場:2012年 是由出版商Millennium Research Group在2011年11月所出版的。 這份英文市場調查報告書價格從美金6995起跳。

簡介

美國的外科用止血劑，組織內密封材料，及防粘黏薄膜的市場預計在老年人增加的影響下，呈現穩定的成長。

本報告提供美國的外科用止血劑·組織內密封材料·防粘黏薄膜的市場相關資料調查分析，產品類型·各材料的市場規模實際成果預測，推動市場的要素/阻礙要素，再加上主要企業的市場佔有率等彙整資料，為您概述為以下內容。

摘要整理

第1章 臨床環境

• 背景
• 治療概要
  • 外科用止血劑·組織內密封材料·防粘黏薄膜治療
  • 治療方法的競爭
  • 新興治療方法及技術
• 報銷指南
• 國家概要
  • 人口統計與經濟
  • 醫療制度
  • 法規環境

第2章 產品

• 概要
• 外科用止血劑
  • 功能
  • 差異化特性
  • 適應
  • 新產品
• 組織內密封材料
  • 功能
  • 差異化特性
  • 適應
  • 新產品
• 防粘黏薄膜
  • 功能
  • 差異化特性
  • 適應
  • 新產品
• 軟組織黏合產品
• 多功能產品

第3章 臨床實驗

• 結束的臨床實驗
• 進行中的臨床實驗

第4章 品牌及競爭分析

• 概要
  • 競爭的短評
  • 詳細的競爭情形
  • 市場佔有率
  • 最近的事項
• 外科用止血劑市場
  • 競爭情形
  • 目前市場佔有率
• 組織內密封材料市場
  • 競爭情形
  • 目前市場佔有率
• 防粘黏薄膜市場
  • 競爭情形
  • 目前市場佔有率

第5章 市場預測

• 概要
  • 市場短評
  • 詳細的市場概要
• 外科用止血劑市場
  • 市場短評
  • 詳細的市場概要
• 組織內密封材料市場
  • 市場短評
  • 詳細的市場概要
• 防粘黏薄膜市場
  • 市場短評
  • 詳細的市場概要

附錄

圖表

目錄

The US market for surgical hemostats, internal tissue sealants, and adhesion barriers continues to show steady market growth, driven by the expanding aging demographic in the US, which will fuel the number of procedures performed that use these products. The market was not significantly impacted by the economic downturn in recent years because physicians and health care facilities continue to see the long-term value of these products in terms of lowering overall procedure costs and increasing favorable outcomes. In addition, the segments in the report remain underpenetrated, which will provide strong growth opportunities over the forecast period, especially as physicians and facilities become increasingly aware of the benefits these products provide. Revenues will also continue to climb as manufacturers release products for expanded indications. In particular, there will be a gradual shift toward the uptake of products that offer multiple functionalities, which are associated with higher prices. Consequently, their adoption will further contribute to revenue gains through 2016. Revenue growth will, however, be curtailed to some extent due to pricing pressures from health care facilities, competing treatments, currently low product awareness, and the rising number of minimally invasive procedures performed, which typically do not require these products. Overall, however, market growth will be positive through 2016.

This report uses a number of methodologies to gather and present data and analysis. At the outset, a large survey of secondary sources is conducted. These sources act as the basis for the primary research stage, which builds and enhances the quantitative and qualitative attributes of the early research.

Secondary sources include

• Government sources:
  • Securities and Exchange Commission filings
  • Food and Drug Administration and patent filings
  • National Center for Health Statistics data
• Surgical hemostat, internal tissue sealant, and adhesion barrier companies:
  • Annual reports, product brochures, corporate profiles, etc.
• Internal databases and reports:
  • Previous reports on similar/related sources
• General Internet searches, medical literature, and newspaper/magazine searches:
  • Identifying various centers of specialization and articles that might provide leads for primary research

The secondary research stage builds the foundation for the primary research.

The primary research methodology has four steps:

Step 1: The first step involves an impartial scan of all the information gathered during the secondary research stage to determine its utility based on the specific requirements of this report. Each piece of information is either discarded or marked as high- or low-priority and then organized appropriately as determined by the structure and sectioning of the report.

Step 2: At this stage, early assumptions are formed as to the implications of the information for the various surgical hemostat, internal tissue sealant, and adhesion barrier market segments. These assumptions are then used to determine hypotheses using both inductive and deductive approaches. On the quantitative front, these hypotheses result in full historical and projected market data sets (market sizes - unit sales, average selling prices [ASPs], and revenues - as well as market shares).

Step 3: At this stage, the research is in position for its most important primary phase - expert interviews. Throughout the secondary research phase, industry and medical experts are identified.

These experts are then contacted by telephone and asked to participate in interviews on recent trends and developments in the industry. Interviews are either conducted at the time of the initial call or scheduled at the convenience of the expert. Interview questions are tailored to the expertise of each particular interviewee, although in most cases, the most important questions are asked of all experts. The questions are largely based on the assumptions and hypotheses developed in Step 2, which are then augmented, discarded, or adjusted based on the views and positions put forth. Attempts are made, whenever possible, to cross-check the views of various experts against each other and to reach positions of consensus on issues and market numbers.

Step 4: The final stage of primary research involves individual and group analysis by Millennium Research Group. All research results are assessed and cross-checked thoroughly to determine their validity, relevance, and weight. From this process, qualitative conclusions are reached and data points finalized.

In addition to the research methodology outlined above, the following “bottom-up” methodology is used to develop forecast assumptions for the report.

A comprehensive breakdown of various surgical hemostat, internal tissue sealant, and adhesion barrier procedures and unit sales is prepared using data from several sources, including professional associations, government statistics, and private research/media sources. Industry experts and practitioners are consulted to ensure accuracy and verify observed trends. As a cross-check, total industry revenues available through annual reports and other sources are compared against modeled industry revenues.

Using the best estimates of industry experts, practitioners, private research/media sources, and inhouse experts, year-by-year growth rates and ASPs are applied individually to each subcategory to derive forecasts. These estimates are cross-checked by industry experts (marketing managers, product managers, CEOs, etc.) and further refined.

Overall findings are compared against market and procedure forecasts published by other sources to ensure reasonable estimates.

Companies mentioned in this report:

• Baxter BioSurgery
• B. Braun
• Confluent Surgical
• Covidien
• CryoLife
• Davol (a C. R. Bard company)
• ETHICON (a Johnson & Johnson company)
• FzioMed
• Genzyme BioSurgery (acquired by Sanofi)
• HyperBranch Medical Technology
• Integra LifeSciences
• King Pharmaceuticals
• Magen Medical Solutions
• MAST Biosurgery
• Medafor
• Medtronic
• NeoMend
• Nycomed
• OMRIX Biopharmaceuticals
• ORTHOCON
• Orthovita (acquired by Stryker)
• Pathfinder Cell Therapy
• Pfizer
• Smith & Nephew
• Starch Medical
• Stryker
• ZymoGenetics (acquired by Bristol-Myers Squibb)

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1.0. CLINICAL LANDSCAPE

• 1.1. Background
• 1.2. Procedure Overview
  • 1.2.1. Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Procedures
  • 1.2.2. Competing Treatments
  • 1.2.3. Emerging Competing Treatments and Technologies
• 1.3. Reimbursement Guidelines
• 1.4. Country Overview
  • 1.4.1. Demographics and Economy
  • 1.4.2. Health Care System
  • 1.4.3. Regulatory Environment

2.0. PRODUCTS

• 2.1. Overview
  • 2.1.1. Products Covered
• 2.2. Surgical Hemostats
  • 2.2.1. Functions
    • 2.2.1.1. Thrombin-Based Surgical Hemostats
    • 2.2.1.2. ORC-Based Surgical Hemostats
    • 2.2.1.3. Combination Surgical Hemostats
    • 2.2.1.4. Gelatin-Based Surgical Hemostats
    • 2.2.1.5. Collagen-Based Surgical Hemostats
    • 2.2.1.6. Autologous-Based Surgical Hemostats
    • 2.2.1.7. Polysaccharide-Based Surgical Hemostats
  • 2.2.2. Differentiating Features
  • 2.2.3. Labeled Indications
  • 2.2.4. Emerging Products
• 2.3. Internal Tissue Sealants
  • 2.3.1. Functions
    • 2.3.1.1. Fibrin-Based Sealants
    • 2.3.1.2. Synthetic-Based Sealants
    • 2.3.1.3. Protein-Based Sealants
  • 2.3.2. Differentiating Features
  • 2.3.3. Labeled Indications
  • 2.3.4. Emerging Products
• 2.4. Adhesion Barriers
  • 2.4.1. Functions
    • 2.4.1.1. Films
    • 2.4.1.2. Hydroflotation
    • 2.4.1.3. Gels
  • 2.4.2. Differentiating Features
  • 2.4.3. Labeled Indications
  • 2.4.4. Emerging Products
• 2.5. Soft Tissue Attachment Products (Qualitative Discussion Only)
• 2.6. Multifunctional Products (Qualitative Discussion Only)

3.0. CLINICAL TRIALS

• 3.1. Completed Clinical Trials
• 3.2. Ongoing Clinical Trials

4.0. BRANDS AND COMPETITIVE ANALYSIS

• 4.1. Overview
  • 4.1.1. Competitive Snapshot
  • 4.1.2. Detailed Competitive Landscape
  • 4.1.3. Market Shares
  • 4.1.4. Recent Events
• 4.2. Surgical Hemostat Market
  • 4.2.1. Competitive Snapshot
  • 4.2.2. Current Market Shares
• 4.3. Internal Tissue Sealant Market
  • 4.3.1. Competitive Snapshot
  • 4.3.2. Current Market Shares
• 4.4. Adhesion Barrier Market
  • 4.4.1. Competitive Snapshot
  • 4.4.2. Current Market Shares

5.0. MARKET OUTLOOK

• 5.1. Overview
  • 5.1.1. Market Snapshot
  • 5.1.2. Detailed Market Overview
• 5.2. Surgical Hemostat Market
  • 5.2.1. Market Snapshot
  • 5.2.2. Detailed Market Overview
    • 5.2.2.1. Thrombin-Based Surgical Hemostat Market
    • 5.2.2.2. Oxidized Regenerated Cellulose-Based Hemostat Market
    • 5.2.2.3. Combination Hemostat Market
    • 5.2.2.4. Gelatin-Based Hemostat Market
    • 5.2.2.5. Collagen-Based Hemostat Market
    • 5.2.2.6. Autologous-Based Hemostat Market
    • 5.2.2.7. Polysaccharide-Based Hemostat Market
• 5.3. Internal Tissue Sealant Market
  • 5.3.1. Market Snapshot
  • 5.3.2. Detailed Market Overview
    • 5.3.2.1. Fibrin-Based Internal Tissue Sealant Market
    • 5.3.2.2. Synthetic-Based Internal Tissue Sealant Market
    • 5.3.2.3. Protein-Based Internal Tissue Sealant Market
• 5.4. Adhesion Barrier Market
  • 5.4.1. Market Snapshot
  • 5.4.2. Detailed Market Overview

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

APPENDIX C: BIBLIOGRAPHY

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

• Figure 1: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, US (US$), 2010 - 2016
• Table 1: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market Landscape, US (US$), 2011 and 2016
• Table 2: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market Leaders, by Product Type and Revenue, US, 2011
• Table 3: Most Promising Emerging Technologies in the Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, US, 2011 - 2016
• Table 4: Expected Key Events in the Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, US, 2012 - 2016
• Table 5: Factors Impacting Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, US, 2011 - 2016
• Table 6: Companies Mentioned in This Report

1.0 CLINICAL LANDSCAPE

• Table 7: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Procedures, by Anatomic Region and Procedure Type, US
• Table 8: Competing Treatments, US
• Table 9: Emerging Competing Treatments and Technologies, US, 2011 - 2016
• Table 10: Key Health and Economic Indicators, US, 2011

2.0 PRODUCTS

• Table 11: Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market, by Product Type, US
• Table 12: Insights and Functionality of Surgical Hemostats, by Product Type and Material
• Table 13: Advantages and Disadvantages of Surgical Hemostats, by Material
• Table 14: Recently Approved Surgical Hemostats, US, 2011
• Table 15: Emerging Products for the Surgical Hemostat Market, US, 2011 - 2016
• Table 16: Insights and Functionality of Internal Tissue Sealants, by Material and Chemical Composition
• Table 17: Advantages and Disadvantages of Internal Tissue Sealants, by Material
• Table 18: Common On-label & Off-label uses of Internal Tissue Sealants
• Table 19: Approved Internal Tissue Sealants, US, 2011
• Table 20: Emerging Products for the Internal Tissue Sealant Market, US, 2011 - 2016
• Table 21: Advantages and Disadvantages of Adhesion Barriers, by Product Type
• Table 22: Approved Adhesion Barriers, US, 2011
• Table 23: Emerging Products for the Adhesion Barrier Market, US, 2011 - 2016

3.0 CLINICAL TRIALS

• Table 24: Summary of A Trial Comparing Wound Drainage and Postoperative Complications With and Without the Use of EVICEL Fibrin Sealant in Thyroidectomy
• Table 25: Summary of the Efficiency of Intercoat (Oxiplex/AP Gel) in Decreasing Intrauterine Adhesions
• Table 26: Summary of the Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty
• Table 27: Summary of the Trial to Evaluate the Hemostatic Effect of Lyostypt versus SURGICEL in Arterial Bypass Anastomosis (COBBANA)
• Table 28: Summary of the Evaluation of an Absorbable Surgical Hemostatic Agent: THROMBI-GEL versus GELFOAM-Thrombin (Control)
• Table 29: Summary of A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty
• Table 30: Summary of the TachoSil versus SURGICEL Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
• Table 31: Summary of A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair
• Table 32: Summary of the Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures
• Table 33: Summary of the NeoMend ProGEL Pleural Air Leak Sealant Post-Approval Study

4.0 BRANDS AND COMPETITIVE ANALYSIS

• Table 34: Leading Competitors in the Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, as a % of Total, US, 2011
• Table 35: Recent Events in the Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, US, 2011
• Table 36: Leading Competitors in the Surgical Hemostat Market, by Material, as a % of Total, US, 2011
• Table 37: Leading Competitors in the Internal Tissue Sealant Market, by Material, as a % of Total, US, 2011
• Table 38: Leading Competitors in the Adhesion Barrier Market, as a % of Total, US, 2011

5.0 MARKET OUTLOOK

• Figure 2: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, as a % of Total, US, 2011 and 2016
• Table 39: Factors Impacting the Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, US, 2011 - 2016
• Table 40: Surgical Hemostat, Internal Tissue Sealant, and Adhesion Barrier Market, by Product Type, US (US$), 2010 - 2016
• Figure 3: Surgical Hemostat Market, by Material, US (US$), 2010 - 2016
• Table 41: Surgical Hemostat Market, by Material, US (US$), 2010 - 2016
• Table 42: Surgical Hemostat Market Growth, by Material, US, 2011 - 2016
• Figure 4: Internal Tissue Sealant Market, by Material, US (US$), 2010 - 2016
• Table 43: Internal Tissue Sealant Market, by Material, US (US$), 2010 - 2016
• Table 44: Internal Tissue Sealant Market Growth, by Material, US, 2011 - 2016
• Figure 5: Adhesion Barrier Market, US (US$), 2010 - 2016
• Table 45: Adhesion Barrier Market, US (US$), 2010 - 2016

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

• MRG Acronyms and Initialisms

APPENDIX C: BIBLIOGRAPHY

Press Release

2016年美國外科用止血劑•組織內密封劑•粘黏物阻隔薄膜市場將達到17億美元規模

相關商品

傷口護理相關市場調查報告書

全球先進型創傷管理市場:開發平台分析，競爭環境，到2018年為止的市場預測
Advanced Wound Management - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
價格 : US $ 3995
出版日期 : 2012年04月

加拿大的傷口敷料市場趨勢:分析及預測
Canada Wound Dressings Market Trends Until 2018
價格 : US $ 2000
出版日期 : 2012年04月

美國的傷口敷料市場趨勢:分析及預測
US Wound Dressings Market Trends Until 2018
價格 : US $ 2000
出版日期 : 2012年04月

Millennium Research Group發行的醫療設備相關市場調查報告書

歐洲的重病患者管理用資訊系統市場:2012年

European Markets for High-Acuity Information Systems 2012

價格 : US $ 5995

出版日期 : 2012年04月

亞太地區的經導管栓塞·阻塞設備市場:2012年

Asia Pacific Markets for Transcatheter Embolization and Occlusion Devices 2012

價格 : US $ 6995

出版日期 : 2012年04月

歐洲的整形外科用軟組織解決方案市場:2012年

European Markets for Orthopedic Soft Tissue Solutions 2012

價格 : US $ 5995

出版日期 : 2012年03月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!